Armed antibodies for cancer treatment: a promising tool in a changing era.

Armed antibodies for cancer treatment: a promising tool in a changing era.

Item
http://www.wikidata.org/entity/Q38260165
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsEmerging formats for next-generation antibody drug conjugates.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationUnleashing the immune response against childhood solid cancers.Intralesional PV-10 for in-transit melanoma-A single-center experience.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.
P2860

Armed antibodies for cancer treatment: a promising tool in a changing era.

Item
http://www.wikidata.org/entity/Q38260165
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Armed antibodies for cancer treatment: a promising tool in a changing era.
@en
type
label
Armed antibodies for cancer treatment: a promising tool in a changing era.
@en
prefLabel
Armed antibodies for cancer treatment: a promising tool in a changing era.
@en
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P356
P1433
P1476
Armed antibodies for cancer treatment: a promising tool in a changing era.
@en
P2093
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698